• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$12.87 $0.15 (1.18%)

REAL-TIME: Last trade at

Ligand Pharmaceuticals, Inc.

NASDAQ:LGND

Jump to this page for:

Related Resources

CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4

5/14/2012 by Business Wire

Ligand Pharmaceuticals, Inc. (LGND) Tops Q1 EPS by 9c

5/2/2012 by StreetInsider.com

Ligand Pharmaceuticals reports Q1 cont ops EPS (3c), consensus (2c)

5/2/2012 by Theflyonthewall.com

Ligand Pharmaceuticals reiterates FY12 revenue around $30M, consensus $33.11M

5/2/2012 by Theflyonthewall.com

Biotechnology And Drugs Stocks To Watch For Next Week

4/25/2012 by Seeking Alpha

Ligand to Report First Quarter Results on May 2nd

4/16/2012 by Business Wire

Ligand to Present at the 24th Annual Roth Conference on March 12

3/5/2012 by Business Wire

Ligand Pharmaceuticals signs deal possibly worth $75 million

3/2/2012 by The San Diego Union Tribune - San Diego CA

Ligand to Present at the Citi Global Health Care Conference on February 28th

2/21/2012 by Business Wire

Ligand Pharmaceuticals licenses DARA program to Retrophin

2/21/2012 by Theflyonthewall.com

Ligand Licenses DARA Program to Retrophin

2/21/2012 by Business Wire

Ligand to Present at the BIO CEO and Investor Conference on February 13

2/9/2012 by Business Wire

Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance

2/7/2012 by StreetInsider.com

Ligand Pharmaceuticals sees NDA filing for Aprela in 2012

2/7/2012 by Theflyonthewall.com

Ligand Pharmaceuticals sees FY12 revenue $30M vs. consensus $32.23M

2/7/2012 by Theflyonthewall.com

Ligand Pharmaceuticals reports Q4 continuing ops EPS 24c vs. consensus 7c

2/7/2012 by Theflyonthewall.com

Ligand Reports Fourth Quarter and Full Year 2011 Financial Results

2/7/2012 by Business Wire

Ligand Names Nishan de Silva, M.D., Vice President of Corporate Development

2/7/2012 by Business Wire

Ligand Pharmaceuticals' Melphalan shows succesful results in Phase II trial

2/2/2012 by Theflyonthewall.com

Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled®, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings

2/1/2012 by Business Wire

Summer Street Starts Ligand Pharma (LGND) at Buy, Sets $22 Price Target

1/13/2012 by StreetInsider.com

Ligand Pharmaceuticals initiated with a Buy at Summer Street

1/13/2012 by Theflyonthewall.com

Ligand unit in license, supply pact with Hospira for Captisol

12/27/2011 by Theflyonthewall.com

Ligand Pharmaceuticals Inc. Enters into Platform Captisol?? License and Supply Agreements With Eli Lilly and Company

12/21/2011 by BioSpace

Ligand Pharmaceuticals enters into agreements with Eli Lilly

12/21/2011 by Theflyonthewall.com

Ligand Enters into Platform Captisol® License and Supply Agreements with Lilly

12/21/2011 by Business Wire

Ligand Pharmaceuticals announces positive preclinical data on GCSF receptor

12/12/2011 by Theflyonthewall.com

Ligand Announces Positive Preclinical Data on Small-Molecule GCSF Receptor Agonist at the 53rd Annual Meeting of the American Society of Hematology

12/12/2011 by Business Wire

Ligand to Present at the Oppenheimer Healthcare Conference on December 14

12/7/2011 by Business Wire

Biotechnology Value raises passive stake in Ligand Pharma to 17.7% from 10.7%

11/23/2011 by Theflyonthewall.com

Insiders Trading DDMG, FCN, CCMO

11/23/2011 by TheStreet.com

Griffin Securities Starts Ligand Pharma (LGND) at Buy; Recent Decline in Share Price Presents A Buying Opportunity

11/22/2011 by StreetInsider.com

Ligand Pharmaceuticals initiated with a Buy at Griffen Securities

11/22/2011 by Theflyonthewall.com

Why Did My Stock Just Die?

11/9/2011 by The Motley Fool

8 Stocks Rising on Unusual Volume

11/9/2011 by TheStreet.com

Ligand Pharmaceuticals Announces Third Quarter Results

11/9/2011 by PharmiWeb.com - UK

Ligand Pharmaceuticals raises FY11 revenue view to approx $26M from $22M-$24M

11/8/2011 by Theflyonthewall.com

Ligand Pharmaceuticals sees Q4 revenue approximately $9M vs. consensus $6.2M

11/8/2011 by Theflyonthewall.com

Ligand Pharmaceuticals reports Q3 EPS (20c) vs. consensus 1c

11/8/2011 by Theflyonthewall.com

Ligand Pharmaceuticals Announces Third Quarter Results

11/8/2011 by Business Wire
See More Articles...